The TakeAim Lymphoma Clinical Trial

The TakeAim Lymphoma trial is a global open-label study for relapsed or refractory primary CNS lymphoma that tests the combination of ibrutinib and emavusertib. Dr. Hamdy explained that the scientific rationale. He highlighted encouraging early results, including manageable safety, rapid tumor responses, and some durable remissions in heavily pretreated patients. The discussion also emphasized that clinical trials, second opinions, and early referral to participating centers are important for patients seeking more options. Key Takeaways Dual inhibition: Preclinical studies suggest the combination works better than either drug alone, supporting the trial’s design. Durability: Some patients have stayed on study for many months, including complete remissions lasting over a year in select cases. Patient access: Dr. Hamdy encouraged patients to ask about clinical trials, seek second opinions, check clinicaltrials.gov, and contact trial teams or participating sites directly. This video was hosted by Dellann Elliott Mydland, cofounder of the End Brain Cancer Initiative (EBCI). Dr. Hamdy was the main speaker. Dr. Nayak and Dr. Grommes participated in the question and answer session. Speaker Credentials Dr. Hamdy is Chief Medical Officer of Curis, joining the Company in May 2025. Prior to joining Curis, he served as CEO and Chairman of the board of directors of Vincerx Pharma, Inc. Prior to Vincerx, Dr. Hamdy co-founded Acerta Pharma, LLC, and served as its CEO and CMO. Before Acerta, Dr. Hamdy was CMO of Pharmacyclics, Inc. Dr. Hamdy is an Adjunct Professor at University of California Santa Cruz Department of Biomolecular Engineering and is a member of the Dean’s Council of the Jack Baskin School of Engineering at the University of California, Santa Cruz. Dr. Hamdy received his MBBCH from the KasrAlainy School of Medicine at the University of Cairo, Egypt. Dr Lakshmi Nayak is a neuro-oncologist, associate professor of neurology at Harvard Medical School, and director of the Center for CNS Lymphoma at Dana-Farber/Harvard-affiliated programs in Boston. Her training includes medical school in Mumbai, residency at NewYork-Presbyterian/Cornell, and fellowship at Memorial Sloan Kettering Cancer Center, and her research focuses on novel therapies for brain tumors and PCNSL, including targeted therapy, immunotherapy, and CAR T-cell approaches. Dr. Christian Grommes is a neuro-oncologist and early drug development specialist at Memorial Sloan Kettering Cancer Center. He focuses on primary brain tumors and CNS lymphomas, conducts research on genetic drivers of PCNSL, and leads clinical trials investigating novel targeted and combination therapies. This video was featured in the “New Developments in PCNSL Treatments” webinar, created by the End Brain Cancer Initiative. They invited members of the Primary Central Nervous System Lymphoma (PCNSL) community to hear directly from top experts in the neuro-oncology field about new research, clinical trials, specialists, treatments, diagnostics, support, and more. The webinar was recorded on March 27th, 2026. This patient disease educational video was made possible with the support of Deciphera, the End Brain Cancer Initiative, and other supporters Learn More: Full webinar video:    • New Developments in PCNSL Treatments   EBCI website: https://endbraincancer.org/ Web page for this event: https://endbraincancer.org/new-develo... Web page for PCNSL: https://endbraincancer.org/pcnsl/ Web page for TakeAIM: https://endbraincancer.org/curis-ther... PCNSL video playlist:   • Primary Central Nervous System Lymphoma   Deciphera website: https://www.deciphera.com/ Subscribe to the End Brain Cancer YouTube channel for more expert conversations on brain cancer treatments, research updates, and patient advocacy: https://www.youtube.com/channel/@EndB... #EndBrainCancer, #PCNSL